EyePoint Pharmaceuticals, Inc.
480 Pleasant Street
Watertown, MA 02472
January 21, 2021
VIA EDGAR
Office of Life Sciences
Division of Corporation Finance
U.S. Securities and Exchange Commission
100 F Street, NE
Washington, DC 20549
Attn: Courtney L. Lindsay II
| Re: | EyePoint Pharmaceuticals, Inc. |
Registration Statement on Form S-3
Filed January 15, 2021
File No. 333-252170
Request for Acceleration of Effective Date
Dear Mr. Lindsay:
Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, EyePoint Pharmaceuticals, Inc. hereby requests that the Securities and Exchange Commission accelerate the effective date of the above-referenced Registration Statement on Form S-3 (the “Registration Statement”), and declare the Registration Statement effective as of 4:00 p.m., Eastern Standard Time, on January 25, 2021, or as soon thereafter as possible.
Please feel free to direct any questions or comments concerning this request to Stephen Nicolai of Hogan Lovells US LLP at (267) 675-4642.
| Very truly yours, | ||
| EyePoint Pharmaceuticals, Inc. | ||
| /s/ Ron Honig, Esq. | ||
| By: | Ron Honig, Esq. | |
| Title: | Senior Vice President, General Counsel and Company Secretary | |